X

Trial Profile

A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ravulizumab (Primary)
Indications Paroxysmal nocturnal haemoglobinuria
Focus Pharmacokinetics; Registrational
Sponsors Alexion AstraZeneca Rare Disease

Most Recent Events

30 Sep 2022 Status changed from recruiting to completed.
21 Sep 2022 This trial has been completed in France, according to European Clinical Trials Database record (25 Aug 2022)
19 Sep 2022 This trial has been completed in Netherlands, according to European Clinical Trials Database record (25 Aug 2022).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com